drugset / Trial / NCT06768840
Vitiligo, New Treatment and Serum s100B
RandomizedParallel-groupOpen-labelTreatment
Summary
vitiligo is an autoimmune depigmenting skin disorder characterized by milky white macules or patches, with 2% worldwide prevalence. Vitiligo has unexpected course that significantly influences on patient's quality of life and self-esteem. Multiple medications have been introduced for vitiligo treatment, in this study we work on one of systemic JAK inhibitors
Timeline
- Start
- 2024-10-02
- Primary completion
- 2025-08
- Completion
- 2025-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Baricitinib | Small molecule | 2 mg | Oral |
| Comparator | Baricitinib | Small molecule | 4 mg | Oral |
| Comparator | Dexamethasone | Small molecule | 1.25 mg | Oral |
| Comparator | Dexamethasone | Small molecule | 2.5 mg | Oral |